Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin

Thoracic and Cardiovascular Surgeon

Volumn 56, Issue 5, 2008, Pages 274-277

  Hata, Mitsumasa ^a   Hayasaka, M ^a   Sezai, A ^a   Niino, T ^a   Yoda, M ^a   Unosawa, S ^a   Taoka, M ^a   Osaka, S ^a   Furukawa, N ^a   Kimura, H ^a   Minami, K ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Cardiovascular surgery; Heart disease; Heart valve surgery

Indexed keywords

ACETYLSALICYLIC ACID; LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HEART TAMPONADE; HEMATOTHORAX; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CARDIAC TAMPONADE; FEMALE; HEMOTHORAX; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; WARFARIN;

EID: 50849142881     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038378     Document Type: Article

References (14)

1. Hata M, Shiono M, Sekino H, Furukawa H, Sezai A, Iida M et al. Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery. Circulation J 2005; 69: 331-334
2. http://www.fda.gov/medwatch/SAFETY/2006/Apr_Pls/Naprapac_PI.pdf, see p. 15-16
3. McCarthy DM, McLaughlin TP, Griffis DL, Yazdani C. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. American J Therapeutics 2003; 10: 330-340
4. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Steroselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-184
5. Unge P, Svedberg LE, Nordgren H, Blom H, Anderson T, Lagersrom PO. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmac 1992; 34: 509-512
6. US Food and Drug Administration. Office of Drug Safety, Annual Report 2001, viewable at: http://www.fda.gov/cder/Offices/drugsafety/ Ann-Rep2001/annualreport2001.htm#AERS%20Reports
7. Levine MN, Rascob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 287S-310S
8. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212
9. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28
10. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 (Suppl 1): S21-S25
11. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530
12. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenitoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-154
13. Ko J-W, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862
14. VandenBranden M, Ring BJ, Binkley SN, Wringhton SA. Interaction of human liver cytochrome P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6: 81-91